Pharmaceutical firm Zydus Cadila on 16 October 2013 signed a drug development and commercialisation agreement with Germany’s Pieris AG for a new therapeutic protein molecule called Anticalin. The agreement brings together Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing.
Zydus has been given exclusive marketing rights in India and several other emerging markets, while Pieris maintains exclusive marketing rights in key developed markets.
The most advanced programme in their collaboration is PRS-110, a target which is increasingly becoming valued across a broad spectrum of tumours.
Through the agreement the companies try to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories.
Who: Zydus Cadila
When: 16 October 2013
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.